Cochrane · systematic review · CD012144
Antithrombotic treatment after stroke due to intracerebral haemorrhage
Cochrane, A, Chen, C, Stephen, J, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
17
No studies
3
Included studies
NR
No studies 3 · 15%Ungraded 0 · 0%Very low 4 · 20%Low 4 · 20%Moderate 9 · 45%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings table ‐ Starting short‐term prophylactic dose anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage
Population: survivors of stroke due to intracerebral haemorrhage
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MACE ‐ not reported Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation | no estimate extracted | NR | No studies |
Death Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation | RR 1 [0.59, 1.7] | 3 studies · 258 participants | Very low Downgraded: risk of bias, imprecision |
Venous thromboembolism Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation | RR 0.84 [0.51, 1.37] | 4 studies · 333 participants | Very low Downgraded: risk of bias, imprecision |
Intracerebral haemorrhage (ICH) Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation | RR 0.24 [0.04, 1.38] | 2 studies · 119 participants | Very low Downgraded: risk of bias, imprecision |
Functional status: mRS 0‐2 Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation | RR 2.03 [0.78, 5.25] | 1 study · 73 participants | Very low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation compared to avoiding anticoagulation for survivors of stroke due to intracerebral haemorrhage with atrial fibrillation
Population: survivors of stroke due to intracerebral haemorrhage with atrial fibrillation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MACE (MACE) Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation | RR 0.61 [0.4, 0.94] | 3 studies · 334 participants | Moderate Downgraded: imprecision |
Death Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation | RR 1.05 [0.62, 1.78] | 3 studies · 334 participants | Moderate Downgraded: imprecision |
All major occlusive vascular events Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation | RR 0.27 [0.14, 0.53] | 3 studies · 334 participants | Moderate Downgraded: imprecision |
Intracranial haemorrhage Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation | RR 2.43 [0.88, 6.73] | 3 studies · 334 participants | Moderate Downgraded: imprecision |
Functional status (mRS 0‐2) Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation | RR 0.98 [0.78, 1.24] | 2 studies · 288 participants | Low Downgraded: imprecision |
Summary of findings table ‐ Starting long‐term oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage
Population: survivors of stroke due to intracerebral haemorrhage
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MACE Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy | RR 0.89 [0.64, 1.22] | 1 study · 536 participants | Moderate |
Death Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy | RR 1.08 [0.76, 1.53] | 1 study · 536 participants | Moderate |
All major occlusive vascular events Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy | RR 1.03 [0.68, 1.55] | 1 study · 536 participants | Moderate |
Intracerebral haemorrhage (ICH) Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy | RR 0.52 [0.27, 1.03] | 1 study · 536 participants | Moderate |
Fnctional status (mRS 0‐2) Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy | RR 0.95 [0.77, 1.18] | 1 study · 461 participants | Moderate |
Summary of findings table ‐ Cilostazol compared to aspirin for adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage
Population: adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral haemorrhage
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MACE Summary of findings table ‐ Cilostazol vs aspirin | RR 1.33 [0.74, 2.4] | 1 study · 288 participants | Low Downgraded: imprecision |
Death Summary of findings table ‐ Cilostazol vs aspirin | RR 1.65 [0.55, 4.91] | 1 study · 288 participants | Low Downgraded: imprecision |
All major occlusive vascular events ‐ not reported Summary of findings table ‐ Cilostazol vs aspirin | no estimate extracted | NR | No studies |
Intracerebral haemorrhage (ICH) Summary of findings table ‐ Cilostazol vs aspirin | RR 1.29 [0.35, 4.69] | 1 study · 288 participants | Low Downgraded: imprecision |
Functional status ‐ not reported Summary of findings table ‐ Cilostazol vs aspirin | no estimate extracted | NR | No studies |
Antithrombotic treatment compared to no antithrombotic treatment for intracerebral haemorrhage
Population: people with intracerebral haemorrhage
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Composite vascular endpoint Antithrombotic treatment vs no antithrombotic treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Death Antithrombotic treatment vs no antithrombotic treatment | RR 1.25 [0.38, 4.07] | 1 study · 46 participants | Low Downgraded: risk of bias |
Growth of ICH Antithrombotic treatment vs no antithrombotic treatment | RR 1.64 [0.51, 5.29] | 2 studies · 121 participants | Low Downgraded: risk of bias |
ICH Antithrombotic treatment vs no antithrombotic treatment | no estimate extracted | 1 study · 75 participants | Low Downgraded: risk of bias |
Major extracerebral haemorrhage Antithrombotic treatment vs no antithrombotic treatment | no estimate extracted | 1 study · 75 participants | Low Downgraded: risk of bias |
Deep vein thrombosis Antithrombotic treatment vs no antithrombotic treatment | RR 0.99 [0.46, 1.96] | 2 studies · 121 participants | Low Downgraded: risk of bias |
Other major ischaemic events Antithrombotic treatment vs no antithrombotic treatment | RR 0.54 [0.23, 1.28] | 2 studies · 121 participants | Low Downgraded: risk of bias |